Analysis of influencing factors of lower extremity arteriosclerosis in patients with type 2 diabetes mellitus

doi:10.3877/cma.j.issn.1673-9450.2024.02.009

Abstract

Abstract:

Objective

To explore the risk factors of lower extremity arteriosclerosis (LEA) in T2DM patients.

Methods

Data of 420 patients with T2DM admitted to Wound Repair Center, Liyuan hospital, Tongji Medical College, Huazhong University of Science and Technology from January 2021 to December 2022 were retrospectively reviewed including 275 patients with LEA and 145 patients without LEA. The data of gender, age, basic diseases (including coronary heart disease, cerebral infarction, hypertension, hyperlipidemia), D-dimer, white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HGB), fasting blood glucose, glycated hemoglobin (HbA1c), complement C1q, alanine transaminase (ALT), aspartate transaminase (AST), triglycerides (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and brain natriuretic peptide (BNP) indicators were collected and analyzied. Data were analyzed by t test, Mann-Whitney U test, chi-square test and logistic regress analysis.

Results

Among 420 patients with T2DM, 275 patients had LEA with the incidence rate of 65.5%, and the remaining 145 patients did not have LEA. Compared between the patients with LEA or not, it was found that coronary heart disease, cerebral infarction, D-dimer, HGB, HbA1c, HDL-C, LDL-C and BNP were posiblely related with LEA in T2DM patients (P<0.05), while the other variables had no statistical significance between the two groups (P>0.05). Univariate logistic regression analysis showed that coronary heart disease, D-dimer, HbA1c, LDL-C and BNP were the influencing factors of LEA (P<0.05). The multivariate logistic regression analysis showed that coronary heart disease, high D-dimer, high HbA1c and high BNP were independent risk factors for T2DM patients with LEA (P<0.05).

Conclusion

Coronary heart disease, high D-dimer, high HbA1c and high BNP are independent risk factors for T2DM patients with LEA.

Key words: Diabetes mellitus, type 2, Arteriosclerosis of lower extremities, Influencing factors, Logistic regression analysis

Hui Wang, Baorui Xue, Gongchi Li, Huizhen Liu, Xia Lei, Binghui Li. Analysis of influencing factors of lower extremity arteriosclerosis in patients with type 2 diabetes mellitus[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(02): 147-152.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhssyxfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1673-9450.2024.02.009

https://zhssyxfzz.cma-cmc.com.cn/EN/Y2024/V19/I02/147

Figures/Tables 5

References 29

[1]	Nativel M, Potier L, Alexandre L, et al. Lower extremity arterial disease in patients with diabetes: a contemporary narrative review[J]. Cardiovasc Diabetol, 2018，17(1)：138.
[2]	Hamilton EJ, Davis WA, Siru R, et al. Temporal trends in incident hospitalization for diabetes-related foot ulcer in type 2 diabetes: the fremantle diabetes study[J]. Diabetes Care, 2021，44(3)：722-730.
[3]	Sampson UK, Fowkes FG, McDermott MM, et al. Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010[J]. Glob Heart, 2014，9(1)：145-158.
[4]	Zhang Y, Lazzarini PA, McPhail SM, et al. Global disability burdens of diabetes-related lower-extremity complications in 1990 and 2016[J]. Diabetes Care, 2020，43(5)：964-974.
[5]	ElSayed NA, Aleppo G, Aroda VR, et al. Classification and diagnosis of diabetes: standards of care in diabetes-2023[J]. Diabetes Care, 2023，46(Suppl 1)：S19-S40.
[6]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)(上)[J]. 中国实用内科杂志，2021，41(8)：668-695.
[7]	毕超. 彩色多普勒超声诊断糖尿病下肢动脉硬化[J]. 中国实验诊断学，2019，23(3)：390-391.
[8]	Faselis C, Katsimardou A, Imprialos K, et al. Microvascular complications of type 2 diabetes mellitus[J]. Curr Vasc Pharmacol, 2020，18(2)：117-124.
[9]	Huebschmann AG, Huxley RR, Kohrt WM, et al. Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course[J]. Diabetologia, 2019，62(10)：1761-1772.
[10]	Da SD, Grande AJ, Roever L, et al. High-intensity interval training in patients with type 2 diabetes mellitus: a systematic review[J]. Curr Atheroscler Rep, 2019，21(2)：8.
[11]	Yang Z, Han B, Zhang H, et al. Association of lower extremity vascular disease, coronary artery, and carotid artery atherosclerosis in patients with type 2 diabetes mellitus[J]. Comput Math Methods Med, 2021，2021：6268856.
[12]	姚立军，陈弹. 瑞舒伐他汀与阿托伐他汀对冠心病患者血脂、动脉粥样硬化程度和血管内皮舒张功能的疗效对比[J]. 中国药房，2017，28(35)：4963-4966.
[13]	中华医学会内分泌学分会．中国成人2型糖尿病患者动脉粥样硬化性脑心血管疾病分级预防指南[J]. 中华内分泌代谢杂志，2016，32(7)：540-545.
[14]	Poredos P, Blinc A. Arteriosclerosis and atherosclerosis of the lower limbs and cardiovascular risk[J]. Atherosclerosis, 2022，340：44-45.
[15]	Jin QH, Ye WL, Chen HH, et al. Levels of brain natriuretic peptide are associated with peripheral arterial disease in subjects with type-2 diabetes mellitus[J]. BMC Endocr Disord, 2014，14：27.
[16]	Kuwahara K. The natriuretic peptide system in heart failure: diagnostic and therapeutic implications[J]. Pharmacol Ther, 2021，227：107863.
[17]	Hendricks S, Dykun I, Balcer B, et al. Higher BNP/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis[J]. ESC Heart Fail, 2022，9(5)：3198-3209.
[18]	Rodriguez-Castro E, Hervella P, Lopez-Dequidt I, et al. NT-pro-BNP: a novel predictor of stroke risk after transient ischemic attack[J]. Int J Cardiol, 2020，298：93-97.
[19]	Park K, Itoh H, Yamahara K, et al. Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases[J]. Endocrinology, 2008，149(2)：483-491.
[20]	Schirger JA, Grantham JA, Kullo IJ, et al. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition[J]. J Am Coll Cardiol, 2000，35(3)：796-801.
[21]	Jouni H, Rodeheffer RJ, Kullo IJ. Increased serum N-terminal pro-B-type natriuretic peptide levels in patients with medial arterial calcification and poorly compressible leg arteries[J]. Arterioscler Thromb Vasc Biol, 2011，31(1)：197-202.
[22]	Domingueti CP, Foscolo RB, Dusse L, et al. Association of different biomarkers of renal function with D-dimer levels in patients with type 1 diabetes mellitus (renal biomarkers and D-dimer in diabetes)[J]. Arch Endocrinol Metab, 2018，62(1)：27-33.
[23]	Papachristoforou E, Lambadiari V, Maratou E, et al. Association of glycemic indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications[J]. J Diabetes Res, 2020，2020：7489795.
[24]	Wieczor R, Kulwas A, Rosc D. Implications of hemostasis disorders in patients with critical limb ischemia-an in-depth comparison of selected factors[J]. J Clin Med, 2020，9(3)：659.
[25]	Musicant SE, Taylor LJ, Peters D, et al. Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease[J]. J Vasc Surg, 2006，43(4)：772-780, 780.
[26]	Gomez-Peralta F, Choudhary P, Cosson E, et al. Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin[J]. Diabetes Obes Metab, 2022，24(4)：599-608.
[27]	Wright LA, Hirsch IB. Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters[J]. Diabetes Technol Ther, 2017，19(S2)：S16-S26.
[28]	Mannucci E, Dicembrini I, Lauria A, et al. Is glucose control important for prevention of cardiovascular disease in diabetes？[J]. Diabetes Care, 2013，36 (Suppl 2)：S259-S263.
[29]	Criqui MH, Aboyans V. Epidemiology of peripheral artery disease[J]. Circ Res, 2015，116(9)：1509-1526.

组别	例数	年龄[岁，M(Q_L，Q_U)]	性别[例(%)]
组别	例数	年龄[岁，M(Q_L，Q_U)]	男	女
LEA组	275	62 (56，69)	166(60.4)	109(39.6)
NLEA组	145	62 (56，68)	76(52.4)	69(47.6)
Z值/ χ²值		0.194	2.457
P值		0.846	0.117

组别	例数	年龄[岁，M(Q_L，Q_U)]	性别[例(%)]
组别	例数	年龄[岁，M(Q_L，Q_U)]	男	女
LEA组	275	62 (56，69)	166(60.4)	109(39.6)
NLEA组	145	62 (56，68)	76(52.4)	69(47.6)
Z值/ χ²值		0.194	2.457
P值		0.846	0.117

项目	LEA组(n＝275)	NLEA组(n＝145)	χ²值/Z值/t值	P值
基础疾病[例(%)]
冠心病	108(39.3)	38(26.2)	7.147	0.008
脑梗死	75(27.3)	27(18.6)	3.865	0.049
高血压	167(60.7)	90(62.1)	0.072	0.788
高脂血症	122(44.4)	74(51.0)	1.697	0.193
D-二聚体[mg/L，M(Q_L，Q_U)]	0.38(0.34，0.43)	0.35(0.30，0.43)	3.000	0.003
WBC[10⁹/L，±s]	5.89±1.33	5.80±1.14	0.708	0.480
RBC(10¹²/L，±s)	4.53±0.51	4.57±0.49	0.661	0.509
HGB(g/L，±s)	139.29±8.10	140.93±8.05	1.977	0.049
HbA1c(%，±s)	9.03±1.18	8.74±1.22	2.561	0.011
C1q(mg/L，±s)	181.13±34.36	175.44±32.70	1.639	0.102
ALT[U/L，M(Q_L，Q_U)]	23.50(20.70，28.00)	24.20(21.70，27.75)	1.138	0.255
AST(U/L，±s)	22.62±5.08	23.43±3.76	1.853	0.065
空腹血糖[mmol/L，M(Q_L，Q_U)]	11.66(11.10，12.62)	11.61(10.96，12.32)	1.505	0.132
TG[mmol/L，M(Q_L，Q_U)]	1.87(1.53，2.33)	1.95(1.62，2.33)	0.868	0.385
TC(mmol/L，±s)	5.10±0.90	5.09±0.51	0.096	0.924
HDL-C(mmol/L，±s)	1.24±0.18	1.20±0.16	1.999	0.046
LDL-C(mmol/L，±s)	2.99±0.86	2.81±0.93	1.990	0.046
BNP[pg/ml，M(Q_L，Q_U)]	85.60(79.30，92.00)	82.60(74.65，89.00)	2.926	0.003

项目	LEA组(n＝275)	NLEA组(n＝145)	χ²值/Z值/t值	P值
基础疾病[例(%)]
冠心病	108(39.3)	38(26.2)	7.147	0.008
脑梗死	75(27.3)	27(18.6)	3.865	0.049
高血压	167(60.7)	90(62.1)	0.072	0.788
高脂血症	122(44.4)	74(51.0)	1.697	0.193
D-二聚体[mg/L，M(Q_L，Q_U)]	0.38(0.34，0.43)	0.35(0.30，0.43)	3.000	0.003
WBC[10⁹/L，±s]	5.89±1.33	5.80±1.14	0.708	0.480
RBC(10¹²/L，±s)	4.53±0.51	4.57±0.49	0.661	0.509
HGB(g/L，±s)	139.29±8.10	140.93±8.05	1.977	0.049
HbA1c(%，±s)	9.03±1.18	8.74±1.22	2.561	0.011
C1q(mg/L，±s)	181.13±34.36	175.44±32.70	1.639	0.102
ALT[U/L，M(Q_L，Q_U)]	23.50(20.70，28.00)	24.20(21.70，27.75)	1.138	0.255
AST(U/L，±s)	22.62±5.08	23.43±3.76	1.853	0.065
空腹血糖[mmol/L，M(Q_L，Q_U)]	11.66(11.10，12.62)	11.61(10.96，12.32)	1.505	0.132
TG[mmol/L，M(Q_L，Q_U)]	1.87(1.53，2.33)	1.95(1.62，2.33)	0.868	0.385
TC(mmol/L，±s)	5.10±0.90	5.09±0.51	0.096	0.924
HDL-C(mmol/L，±s)	1.24±0.18	1.20±0.16	1.999	0.046
LDL-C(mmol/L，±s)	2.99±0.86	2.81±0.93	1.990	0.046
BNP[pg/ml，M(Q_L，Q_U)]	85.60(79.30，92.00)	82.60(74.65，89.00)	2.926	0.003

自变量	变量说明	赋值情况
基础疾病-冠心病	分类变量	无＝0，有＝1
基础疾病-脑梗死	分类变量	无＝0，有＝1
D-二聚体	连续变量	-
HGB	连续变量	-
HbA1c	连续变量	-
HDL-C	连续变量	-
LDL-C	连续变量	-
BNP	连续变量	-

Please choose a citation manager

Content to export